
The episode discusses the intersection of inflammation and fibrosis in inflammatory bowel disease, focusing on the potential of TL1A inhibition.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/HRC865. CME/AAPA/IPCE credit will be available until June 3, 2027. At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA. Disclosure information is available at the beginning of the video presentation.
Guests: Anita Afzali, MD, MPH, MHCM, FACG, AGAF, Jessica R. Allegretti, MD, MPH, FACG, AGAF, Millie D. Long, MD, MPH
Merck & Co., Inc.
Organizations: PVI, PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC)
Explore listener stats, chart rankings, contacts and more on the PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast podcast page.